세계의 속효성 인슐린 시장 보고서(2025년)

Short-Acting Insulin Global Market Report 2025

US $ 4,490 ￦ 6,301,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,108,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,914,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

속효성 인슐린 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 정부의 이니셔티브와 지원 증가, 빠른 생산 혁신, 인슐린 치료법 채택 증가, 그리고 개인 맞춤형 의학의 확장에 기인할 수 있습니다. 이 기간에 예상되는 주요 동향으로는 인슐린 전달 장치와 기술의 발전, 혁신적인 속효형 인슐린 아날로그의 개발, 바이오시밀러의 대두, 환자 중심의 치료로의 시프트, 인슐린 제형의 개량 등이 있습니다.

1형 당뇨병의 유병률의 상승은 속효성 인슐린 시장의 성장을 견인할 것으로 예측됩니다. 제1형 당뇨병의 발생률 증가는 유전적 요인, 환경적 요인, 그리고 자가면역 질환의 증가에 의해 영향을 받습니다. 속효성 인슐린은 신속한 혈당 조절을 제공하고 신체의 자연적인 인슐린 반응을 모방함으로써 이 상태를 관리하는데 있어서 중요한 역할을 하고 있습니다. Diabetes Australia는 2023년에, 2022년에는 약 13만 4,000명의 호주인이 1형 당뇨병을 앓고 있어 그 수는 13만 5,423명으로 증가하고 있다고 보고했습니다. 그 결과, 1형 당뇨병의 유병률 증가가 속효성 인슐린 시장의 확대에 박차를 가하고 있습니다.

속효성 인슐린 시장의 주요 기업은 인슐린 포드와 같은 혁신적인 제품을 개발하고, 인슐린 전달을 강화하고, 당뇨병 환자의 어드히어런스를 향상시키고 있습니다. 주입을 제공하는 튜브리스 웨어러블 인슐린 전달 시스템입니다. GO의 FDA 인가를 취득했습니다.이 튜브리스로 장착 가능한 디바이스는 별도의 컨트롤러를 필요로 하지 않고 지속적으로 인슐린을 투여합니다. 매일의 주사의 필요성을 없애, 미리 프로그램된 인슐린 속도를 제공하는 것으로, GO는 당뇨병 관리를 간소화합니다. 사용하기 쉬운 디자인과 약국에서의 가용성은 환자와 건강 관리 제공업체 모두에게 편의성을 높이고 혁신적인 기술을 통해 당뇨병 치료를 진보시키는 인슐렛의 헌신을 강화하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 속효성 인슐린 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 속효성 인슐린 시장 : 성장률 분석
• 세계의 속효성 인슐린 시장 실적 : 규모와 성장, 2019-2024
• 세계의 속효성 인슐린 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계의 속효성 인슐린 전체 규모 시장(TAM)

제6장 시장 세분화

• 세계의 속효성 인슐린 시장 : 처방별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 통상의 인슐린
• 속효형 인슐린
• 세계의 속효성 인슐린 시장 : 제형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 바이알
• 프리필드 펜
• 카트리지
• 세계의 속효성 인슐린 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 피하
• 정맥내
• 세계의 속효성 인슐린 시장 : 환자 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 1형 당뇨병
• 2형 당뇨병
• 세계의 속효성 인슐린 시장 : 유통채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 약국
• 병원 약국
• 온라인 약국
• 세계의 속효성 인슐린 시장 : 레귤러 인슐린유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 인간 정규 인슐린
• 동물 유래 레귤러 인슐린
• 기타 일반 인슐린
• 세계의 속효성 인슐린 시장 : 속효형 인슐린유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 인슐린 리스프로
• 인슐린 아스파르트
• 인슐린 룰 리신

제7장 지역별/국가별 분석

• 세계의 속효성 인슐린 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 속효성 인슐린 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 속효성 인슐린 시장 : 경쟁 구도
• 속효성 인슐린 시장 : 기업 프로파일
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Sumitomo Pharma Co. Ltd.
• Biocon Limited
• Kissei Pharmaceutical Co. Ltd.
• Lupin Limited
• Wockhardt Ltd.
• Lannett Co. Inc.
• MannKind Corporation
• Sihuan Pharmaceutical Holdings Group Ltd.
• Julphar(Gulf Pharmaceutical Industries)
• Geropharm LLC
• Bioton SA
• hec pharm co. ltd
• ADOCIA SAS
• Gan & Lee Pharmaceuticals Co. Ltd.
• Adocia SAS

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 속효성 인슐린 시장 2029 : 새로운 기회를 제공하는 국가
• 속효성 인슐린 시장 2029 : 새로운 기회를 제공하는 부문
• 속효성 인슐린 시장 2029 : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

SHW

영문 목차

영문목차

Short-acting insulin is a type of insulin used to manage blood sugar levels during or after meals. It begins acting within 30 minutes to 1 hour, peaks around 2-3 hours, and lasts for approximately 4-6 hours. This insulin type plays a crucial role in glucose regulation by promoting glucose uptake into cells for energy, particularly after food consumption.

The main formulations of short-acting insulin include regular insulin and rapid-acting insulin. Regular insulin is a fast-acting insulin variant used to control blood sugar levels, typically administered before meals. These formulations are available in various dosage forms, including vials, pre-filled pens, and cartridges, and can be administered via subcutaneous or intravenous routes. Short-acting insulin is prescribed for both type 1 and type 2 diabetes patients and is distributed through retail pharmacies, hospital pharmacies, and online pharmacies.

The short-acting insulin market research report is one of a series of new reports from The Business Research Company that provides short-acting insulin market statistics, including the short-acting insulin industry global market size, regional shares, competitors with the short-acting insulin market share, detailed short-acting insulin market segments, market trends, and opportunities, and any further data you may need to thrive in the short-acting insulin industry. This short-acting insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The short-acting insulin market size has grown strongly in recent years. It will grow from $11.00 billion in 2024 to $11.65 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to the increasing type 1 diabetes population, a rising geriatric population, a surge in research and development funding, a higher prevalence of diagnosed cases, and growing urbanization.

The short-acting insulin market size is expected to see strong growth in the next few years. It will grow to $14.47 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be attributed to increased government initiatives and support, rapid innovations in production, the rising adoption of insulin therapy, and the expansion of personalized medicine. Key trends expected during this period include advancements in insulin delivery devices and technologies, the development of innovative fast-acting insulin analogs, the rise of biosimilars, a shift toward patient-centric care, and improvements in insulin formulation.

The rising prevalence of type 1 diabetes is expected to drive the growth of the short-acting insulin market. Type 1 diabetes is an autoimmune condition in which the body destroys insulin-producing cells, necessitating lifelong insulin therapy. The increasing incidence of type 1 diabetes is influenced by genetic factors, environmental triggers, and a rise in autoimmune disorders. Short-acting insulin plays a crucial role in managing the condition by providing rapid blood sugar control and mimicking the body's natural insulin response. For example, in 2023, Diabetes Australia, an organization dedicated to raising awareness about diabetes, reported that approximately 134,000 Australians were living with type 1 diabetes in 2022, a number that increased to 135,423 in 2023. As a result, the growing prevalence of type 1 diabetes is fueling the expansion of the short-acting insulin market.

Leading companies in the short-acting insulin market are developing innovative products such as insulin pods to enhance insulin delivery and improve adherence for diabetes patients. An insulin pod is a tubeless, wearable insulin delivery system that provides continuous insulin infusion for diabetes management. In April 2023, Insulet Corporation, a US-based medical device company, received FDA clearance for Omnipod GO, a pioneering basal-only insulin pod designed for adults with type 2 diabetes. This tubeless, wearable device delivers continuous insulin without requiring a separate controller. By eliminating the need for daily injections and offering pre-programmed insulin rates, Omnipod GO simplifies diabetes management. Its user-friendly design and pharmacy accessibility enhance convenience for both patients and healthcare providers, reinforcing Insulet's commitment to advancing diabetes care through innovative technology.

In December 2024, Lupin Limited, an India-based pharmaceutical company, acquired the Humulin range in India from Eli Lilly & Company for an undisclosed amount. This acquisition strengthens Lupin's position in the Indian insulin market by expanding its product portfolio with the addition of Huminsulin from Eli Lilly & Company. Eli Lilly & Company, a US-based pharmaceutical firm, specializes in insulin products, including short-acting insulin, further reinforcing Lupin's commitment to providing comprehensive diabetes care solutions.

Major players in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Baxter International Inc., Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Biocon Limited, Kissei Pharmaceutical Co. Ltd., Lupin Limited, Wockhardt Ltd., Lannett Co. Inc., MannKind Corporation, Sihuan Pharmaceutical Holdings Group Ltd., Julphar(Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., hec pharm co. ltd, ADOCIA SAS, Gan & Lee Pharmaceuticals Co. Ltd., and Adocia S.A.S.

North America was the largest region in the short-acting insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in short-acting insulin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the short-acting insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The short-acting insulin market consists of sales of human insulin, analogue insulin, and biosimilars. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Short-Acting Insulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on short-acting insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for short-acting insulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The short-acting insulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Formulation: Regular Insulin; Rapid-Acting Insulin
• 2) By Dosage Form: Vials; Pre-filled Pens; Cartridges
• 3) By Route Of Administration: Subcutaneous; Intravenous
• 4) By Patient Type: Type 1 Diabetes; Type 2 Diabetes
• 5) By Distribution Channel: Pharmacies; Hospital Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Regular Insulin: Human Regular Insulin; Animal-Derived Regular Insulin; Other Regular Insulin
• 2) By Rapid-Acting Insulin: Insulin Lispro; Insulin Aspart; Insulin Glulisine
• Companies Mentioned: Sanofi S.A.; Eli Lilly and Company; Novo Nordisk A/S; Baxter International Inc.; Eisai Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Short-Acting Insulin Market Characteristics

3. Short-Acting Insulin Market Trends And Strategies

4. Short-Acting Insulin Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Short-Acting Insulin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Short-Acting Insulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Short-Acting Insulin Market Growth Rate Analysis
• 5.4. Global Short-Acting Insulin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Short-Acting Insulin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Short-Acting Insulin Total Addressable Market (TAM)

6. Short-Acting Insulin Market Segmentation

• 6.1. Global Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regular Insulin
• Rapid-Acting Insulin
• 6.2. Global Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vials
• Pre-filled Pens
• Cartridges
• 6.3. Global Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous
• Intravenous
• 6.4. Global Short-Acting Insulin Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Diabetes
• Type 2 Diabetes
• 6.5. Global Short-Acting Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.6. Global Short-Acting Insulin Market, Sub-Segmentation Of Regular Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Regular Insulin
• Animal-Derived Regular Insulin
• Other Regular Insulin
• 6.7. Global Short-Acting Insulin Market, Sub-Segmentation Of Rapid-Acting Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Lispro
• Insulin Aspart
• Insulin Glulisine

7. Short-Acting Insulin Market Regional And Country Analysis

• 7.1. Global Short-Acting Insulin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Short-Acting Insulin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Short-Acting Insulin Market

• 8.1. Asia-Pacific Short-Acting Insulin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Short-Acting Insulin Market

• 9.1. China Short-Acting Insulin Market Overview
• 9.2. China Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Short-Acting Insulin Market

• 10.1. India Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Short-Acting Insulin Market

• 11.1. Japan Short-Acting Insulin Market Overview
• 11.2. Japan Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Short-Acting Insulin Market

• 12.1. Australia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Short-Acting Insulin Market

• 13.1. Indonesia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Short-Acting Insulin Market

• 14.1. South Korea Short-Acting Insulin Market Overview
• 14.2. South Korea Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Short-Acting Insulin Market

• 15.1. Western Europe Short-Acting Insulin Market Overview
• 15.2. Western Europe Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Short-Acting Insulin Market

• 16.1. UK Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Short-Acting Insulin Market

• 17.1. Germany Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Short-Acting Insulin Market

• 18.1. France Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Short-Acting Insulin Market

• 19.1. Italy Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Short-Acting Insulin Market

• 20.1. Spain Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Short-Acting Insulin Market

• 21.1. Eastern Europe Short-Acting Insulin Market Overview
• 21.2. Eastern Europe Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Short-Acting Insulin Market

• 22.1. Russia Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Short-Acting Insulin Market

• 23.1. North America Short-Acting Insulin Market Overview
• 23.2. North America Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Short-Acting Insulin Market

• 24.1. USA Short-Acting Insulin Market Overview
• 24.2. USA Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Short-Acting Insulin Market

• 25.1. Canada Short-Acting Insulin Market Overview
• 25.2. Canada Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Short-Acting Insulin Market

• 26.1. South America Short-Acting Insulin Market Overview
• 26.2. South America Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Short-Acting Insulin Market

• 27.1. Brazil Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Short-Acting Insulin Market

• 28.1. Middle East Short-Acting Insulin Market Overview
• 28.2. Middle East Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Short-Acting Insulin Market

• 29.1. Africa Short-Acting Insulin Market Overview
• 29.2. Africa Short-Acting Insulin Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Short-Acting Insulin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Short-Acting Insulin Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Short-Acting Insulin Market Competitive Landscape And Company Profiles

• 30.1. Short-Acting Insulin Market Competitive Landscape
• 30.2. Short-Acting Insulin Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Short-Acting Insulin Market Other Major And Innovative Companies

• 31.1. Sumitomo Pharma Co. Ltd.
• 31.2. Biocon Limited
• 31.3. Kissei Pharmaceutical Co. Ltd.
• 31.4. Lupin Limited
• 31.5. Wockhardt Ltd.
• 31.6. Lannett Co. Inc.
• 31.7. MannKind Corporation
• 31.8. Sihuan Pharmaceutical Holdings Group Ltd.
• 31.9. Julphar(Gulf Pharmaceutical Industries)
• 31.10. Geropharm LLC
• 31.11. Bioton S.A.
• 31.12. hec pharm co. ltd
• 31.13. ADOCIA SAS
• 31.14. Gan & Lee Pharmaceuticals Co. Ltd.
• 31.15. Adocia S.A.S.

32. Global Short-Acting Insulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Short-Acting Insulin Market

34. Recent Developments In The Short-Acting Insulin Market

35. Short-Acting Insulin Market High Potential Countries, Segments and Strategies

• 35.1 Short-Acting Insulin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Short-Acting Insulin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Short-Acting Insulin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료